Cargando…

Differences in Cancer-Specific Mortality after Trimodal Therapy for T2N0M0 Bladder Cancer according to Histological Subtype

SIMPLE SUMMARY: Trimodal therapy represents an accepted treatment option for non-metastatic muscle-invasive bladder cancer, which is an alternative to radical cystectomy. Evidence regarding trimodal therapy efficacy has predominantly, or even exclusively, been applied to urothelial carcinoma of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barletta, Francesco, Tappero, Stefano, Panunzio, Andrea, Incesu, Reha-Baris, Cano Garcia, Cristina, Piccinelli, Mattia Luca, Tian, Zhe, Gandaglia, Giorgio, Moschini, Marco, Terrone, Carlo, Antonelli, Alessandro, Tilki, Derya, Chun, Felix K. H., de Cobelli, Ottavio, Saad, Fred, Shariat, Shahrokh F., Montorsi, Francesco, Briganti, Alberto, Karakiewicz, Pierre I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736026/ https://www.ncbi.nlm.nih.gov/pubmed/36497246 http://dx.doi.org/10.3390/cancers14235766

Ejemplares similares

Survival of Testicular Pure Teratoma vs. Mixed Germ Cell Tumor Patients in Primary Tumor Specimens across All Stages
por: Cano Garcia, Cristina, et al.
Publicado: (2023)

Survival of Testicular Pure Embryonal Carcinoma vs. Mixed Germ Cell Tumor Patients across All Stages
por: Cano Garcia, Cristina, et al.
Publicado: (2023)

Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma
por: Piccinelli, Mattia L., et al.
Publicado: (2023)

Regional differences in clear cell metastatic renal cell carcinoma patients across the USA
por: Scheipner, Lukas, et al.
Publicado: (2023)

Critical Appraisal of Leibovich 2018 and GRANT Models for Prediction of Cancer-Specific Survival in Non-Metastatic Chromophobe Renal Cell Carcinoma
por: Piccinelli, Mattia Luca, et al.
Publicado: (2023)

In-Hospital Venous Thromboembolism and Pulmonary Embolism After Major Urologic Cancer Surgery
por: Cano Garcia, Cristina, et al.
Publicado: (2023)

Grade and stage misclassification in intermediate unfavorable‐risk prostate cancer radiotherapy candidates
por: Sorce, Gabriele, et al.
Publicado: (2022)

Efficacy of chemotherapy on overall survival in metastatic sarcomatoid bladder cancer patients
por: Tappero, Stefano, et al.
Publicado: (2022)

Prognostic Significance of Pathologic Lymph Node Invasion in Metastatic Renal Cell Carcinoma in the Immunotherapy Era
por: Scheipner, Lukas, et al.
Publicado: (2023)

Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy: Extended, of Course
por: Gandaglia, Giorgio, et al.
Publicado: (2022)

Effect of Inferior Vena Cava Tumor Thrombus on Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Cytoreductive Nephrectomy
por: Hoeh, Benedikt, et al.
Publicado: (2022)

Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy
por: Hoeh, Benedikt, et al.
Publicado: (2022)

Demographics, Clinical Characteristics and Survival Outcomes of Primary Urinary Tract Malignant Melanoma Patients: A Population-Based Analysis
por: Morra, Simone, et al.
Publicado: (2023)

Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients
por: Flammia, Rocco S., et al.
Publicado: (2022)

Penile rehabilitation after radical prostatectomy: does it work?
por: Gandaglia, Giorgio, et al.
Publicado: (2015)

Racial/ethnic disparities in the distribution and effect of type and number of high-risk criteria on mortality in prostate cancer patients treated with radiotherapy
por: Chierigo, Francesco, et al.
Publicado: (2022)

Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
por: Wenzel, Mike, et al.
Publicado: (2021)

Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
por: Wenzel, Mike, et al.
Publicado: (2023)

Prostate Cancer: Is There Still a Role for Systematic Biopsies? Yes
por: Gandaglia, Giorgio, et al.
Publicado: (2022)

Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer
por: Hoeh, Benedikt, et al.
Publicado: (2022)

Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients
por: Hoeh, Benedikt, et al.
Publicado: (2021)

North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients
por: Preisser, Felix, et al.
Publicado: (2018)

Primary lymphomas of the genitourinary tract: A population-based study
por: Palumbo, Carlotta, et al.
Publicado: (2020)

Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy
por: Moschini, Marco, et al.
Publicado: (2017)

Anastomotic leaks and catheter time after salvage robot-assisted radical prostatectomy
por: Bandini, Marco, et al.
Publicado: (2018)

An Explanatory Case on the Limitations of Lymph Node Staging in Recurrent Prostate Cancer
por: Bandini, Marco, et al.
Publicado: (2017)

Differences in rates of pelvic lymph node dissection in National Comprehensive Cancer Network favorable, unfavorable intermediate- and high-risk prostate cancer across United States SEER registries
por: Flammia, Rocco Simone, et al.
Publicado: (2022)

Has the COVID-19 outbreak changed the way we are treating prostate cancer? An EAU – YAU Prostate Cancer Working Group multi-institutional study
por: Zattoni, Fabio, et al.
Publicado: (2021)

External Tertiary-Care-Hospital Validation of the Epidemiological SEER-Based Nomogram Predicting Downgrading in High-Risk Prostate Cancer Patients Treated with Radical Prostatectomy
por: Cano Garcia, Cristina, et al.
Publicado: (2023)

Contemporary seminal vesicle invasion rates in NCCN high‐risk prostate cancer patients
por: Flammia, Rocco S., et al.
Publicado: (2022)

Predicting the probability of pT3 or higher pathological stage at radical prostatectomy: COVID19-specific considerations
por: Nocera, Luigi, et al.
Publicado: (2022)

Salvage Radical Prostatectomy for Radio-Recurrent Prostate Cancer: An Updated Systematic Review of Oncologic, Histopathologic and Functional Outcomes and Predictors of Good Response
por: Grubmüller, Bernhard, et al.
Publicado: (2021)

Trimodal therapy in T2‐4aN0M0 bladder cancer––How to select the best candidate?
por: Gofrit, Ofer N., et al.
Publicado: (2020)

Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer
por: Gandaglia, Giorgio, et al.
Publicado: (2023)

Focal therapy for prostate cancer: what is really needed to move from investigational to valid therapeutic alternative?—a narrative review
por: Pellegrino, Antony, et al.
Publicado: (2022)

Sex-related differences in non-urothelial variant histology, non-muscle invasive bladder cancer
por: Flammia, Rocco Simone, et al.
Publicado: (2022)

Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities
por: Würnschimmel, Christoph, et al.
Publicado: (2021)

Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables
por: Würnschimmel, Christoph, et al.
Publicado: (2022)

Survival after radical prostatectomy versus radiation therapy in clinical node‐positive prostate cancer
por: Chierigo, Francesco, et al.
Publicado: (2022)

The association of the type and number of D’Amico high-risk criteria with rates of pathologically non-organ-confined prostate cancer
por: Chierigo, Francesco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_shg8o0umh82v25ibm2sop4mqfa